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Aim: Talimogene laherparepvec (T-VEC) is an intralesional therapy for unresectable, metastatic melanoma.
T-VEC real-world use in the context of anti-PD1-based therapy requires further characterization. Materials
& methods: A retrospective review of T-VEC use from 1 January 2017 and 31 March 2018 for melanoma
patients was conducted at seven US institutions. Results: Among 83 patients, three categories of T-VEC
and anti-PD-1 therapy were identified: T-VEC used without anti-PD-1 (n = 29, 35%), T-VEC after anti-PD1-based therapy (n = 22, 27%) and concurrent T-VEC and anti-PD-1-based therapy (n = 32, 39%). 25% of
patients discontinued T-VEC therapy due to no remaining injectable lesions, 37% discontinued T-VEC due
to progressive disease. Discontinuation of T-VEC did not differ by anti-PD-1-based therapy use or timing.
Conclusion: In real-world settings, T-VEC may be used concurrently with or after anti-PD-1-based therapy.
First draft submitted: 3 April 2020; Accepted for publication: 28 May 2020; Published online:
15 June 2020
Keywords: combination therapy • immunotherapy • metastatic melanoma • oncolytic virus • real-world evidence •

talimogene laherparepvec • T-VEC

Talimogene laherparepvec (T-VEC) is an intralesional oncolytic virus that received US FDA approval in October
2015 for local (intralesional injection) treatment of unresectable cutaneous, subcutaneous and nodal lesions in
patients with melanoma recurrent after initial surgery on the basis of the OPTiM trial [1]. This study compared
intralesional T-VEC and GM-CSF and reported significantly improved overall response rate (ORR) and durable
response rate (DRR) with T-VEC therapy. A recently published final update of the OPTiM trial reported an
estimated 5-year survival of 33.4% for the T-VEC arm and confirmed that T-VEC is more effective in patients
with early metastatic disease (stage IIIB–IVM1a) [2]. Furthermore, of the 17% of patients that achieved complete
response (CR), the median duration of response and OS were not reached over a median follow-up time of greater
than 4 years (49 months). Coupled with low rates of serious (grade ≥3) adverse events, these data demonstrate that
T-VEC therapy is beneficial for patients with stage IIIB–IVM1a disease with durable response and continues to be
an important treatment option.
Studies of real-world T-VEC use have reported similar response rates. One study reported a locoregional ORR of
57% (CR + partial response [PR], 39% + 18%) over a median follow-up time of 9 months [3]. A prior observational
study, COSMUS-1, reported a CR in 20% of patients after T-VEC injections [4]. Both studies identify that the
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Table 1. Number of patients enrolled in study from each participating institution.
Institution

Enrolled patients, n

1

19

2

18

3

12

4

10

5

9

6

8

7

7

Total

83

majority of patients were treated with T-VEC as second- or later-line therapy in the clinical setting and that most
patients have received prior systemic immunotherapy.
In the era of effective systemic immunotherapy, it is important to characterize the real-world use of T-VEC in relation to these therapies. Immunotherapies revolutionized the treatment of advanced melanoma with improvements
in survival and are now standard of care for advanced disease [5]. The two major mechanisms are the inhibition
of PD-1 and CTLA-4, which lead to the activation of T cells (see Bhandaru et al. and Marhelava et al. for detailed
descriptions of mechanisms of action) [6,7]. Approximately 50% of patients do not respond to anti-PD-1 therapy,
and mechanisms of resistance are due to lack of T-cell priming or T-cell infiltration into the tumor [8,9]. Combining
T-VEC and immunotherapy can benefit from the mechanisms of action of both treatment modalities, which may
have a synergistic effect [10–12]. Intratumoral T-VEC injection increases local T-cell recruitment, which augments
immune-mediated anti-tumor responses [8,13,14]. Given the evidence that T-VEC and immunotherapy have synergistic effects, the goal of this study was to describe real-world patterns of T-VEC use and physician attitudes toward
its role in current treatment regimens.
Materials & methods
Study design

COSMUS-2 is a retrospective chart review of melanoma patients treated with T-VEC at seven high-volume
academic centers and specialty clinics in USA. The number of patients enrolled from each institution is described
in Table 1. The primary objectives of this study were to describe the clinical characteristics of patients treated with
T-VEC. The secondary objective was to describe T-VEC use, characterize the use of other therapies and evaluate
other clinical outcome of T-VEC such as safety. Institutional Review Board approval was obtained at each of the
seven participating institutions.
Patient selection

To be eligible for the study, patients must have started their first T-VEC treatment between 1 January 2017 and
31 March 2018. Patients were excluded if they received T-VEC in a clinical trial or expanded access program. Per
the protocol, data were abstracted from medical records by trained abstractors at selected institutions that treat
melanoma patients with T-VEC and agreed to participate in this chart review. Consecutive cases were identified
within the defined study period to avoid selection bias. Sites were instructed to enroll all eligible patients treated
with T-VEC within the study period. Data collected including patient demographics (age, sex), treatment details
and clinical characteristics (Eastern Cooperative Oncology Group Performance Status [ECOG-PS], disease stage,
and BRAF mutation status). Patients were restaged at study initiation according to the American Joint Commission
on Cancer 8th edition staging manual [15].
Statistical analysis

We analyzed T-VEC use in relation to the use of checkpoint inhibitors. Patients were categorized into three groups:
initiation of T-VEC after anti-PD-1 inhibitor therapy, initiation of T-VEC concurrently with anti-PD-1 inhibitor
therapy, initiation of T-VEC without anti-PD-1 inhibitor therapy. A consecutive medical chart review was done at
the seven US-based academic centers to provide patient-level descriptive data of patients administered with T-VEC
during routine clinical practice with the first T-VEC dose given between 1 January 2017 and 31 March 2018.
Charts were reviewed between 1 January 2017 and 31 March 2019. Patients with any history of being a subject in
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Table 2. Demographic, pathologic and treatment characteristics of study cohort.
Characteristics

Overall cohort
(n = 83)

T-VEC after PD-1
(n = 22)

T-VEC concurrent
with PD-1 (n = 32)

T-VEC without PD-1
(n = 29)

Age (median, IQR)

67 years (58–76)

62 years (57–75)

64 years (58–74)

71 years (64–77)

Sex (%)
– Males
– Females

41 (49)
42 (51)

9 (41)
13 (59)

20 (63)
12 (38)

12 (41)
17 (59)

ECOG (%)
– 0
– 1
– 2
– Unknown

33 (40)
27 (33)
5 (6)
18 (22)

6 (27)
6 (27)
3 (14)
7 (32)

14 (44)
11 (34)
1 (3)
6 (19)

13 (45)
10 (34)
1 (3)
5 (17)

BRAF status (%)
– Wild-type
– Mutant
– Unknown

49 (59)
19 (23)
15 (18)

12 (55)
6 (27)
4 (18)

18 (56)
8 (25)
6 (19)

19 (66)
5 (17)
5 (17)

Prior therapies to T-VEC initiation (%)
– Anti-CTLA4
– BRAF/MEK

26 (33)
6 (7)

14 (64)
5 (23)

11 (34)
1 (3)

1 (3)
–

Concurrent therapies with T-VEC (%)
– Anti-CTLA4
– BRAF/MEK

6 (7)
4 (5)

1 (5)
2 (9)

5 (16)
–

–
2 (7)

Disease stage† at first T-VEC injection (%)
– IIIB
– IIIC
– IIID
– IVM1a
– IVM1b
– IVM1c
– IVM1d
– Unknown

19 (23)
31 (37)
1 (1)
12 (14)
4 (5)
11 (13)
1 (1)
4 (5)

3 (14)
6 (27)
–
7 (32)
–
4 (18)
–
2 (9)

7 (22)
12 (38)
1 (3)
3 (9)
2 (6)
5 (16)
–
2 (6)

9 (31)
13 (45)
–
2 (7)
2 (7)
2 (7)
1 (3)
–

T-VEC exposure
– Cumulative volume T-VEC delivered (ml median, range)
– Treatment duration‡ (months, range)
– Number of visits (range)

12.1 (0.6–120.5)
3 (0–20)
7 (1–30)

9 (2–21)
2 (0–20)
5 (1–15)

16.5 (1.5–120.50)
5 (0–17)
8 (2–30)

14.7 (0.6–100.5)
3 (1–15)
7 (2–25)

T-VEC ongoing (%)
– T-VEC discontinuation

9 (11)
74 (89)

–
22 (100)

7 (22)
25 (78)

2 (7)
27 (93)

Reason for discontinuation (if known) (%)§
– No remaining injectable disease
– Progressive disease
– Adverse event
– Death
– Patient preference

21 (25)
31 (37)
8 (10)
8 (10)
4 (5)

5 (23)
12 (55)
4 (18)
2 (9)
2 (9)

8 (25)
9 (28)
3 (9)
5 (16)
–

8 (28)
10 (34)
1 (3)
1 (3)
2 (7)

† Staging

reflected either AJCC 7 or 8.
those whose treatment has ended.
§ Patients could have more than one reason for discontinuation. Eight patients received an anti-PD-1 after T-VEC.
AJCC: American Joint Committee on Cancer; ECOG: Eastern Cooperative Oncology Group; IQR: Interquartile range; T-VEC: Talimogene laherparepvec.
‡ Among

a clinical trial or expanded access program for T-VEC were excluded. Only select adverse events in the categories
of herpetic events, systemic and injection-site complications were collected. An additional survey was provided to
each center to assess physician decision-making considerations toward T-VEC use. All analyses were descriptive, no
formal comparisons were conducted. Analysis was performed using Stata v15.1 or higher (Stata Corp. [2017] Stata
Statistical Software Release 15; StataCorp LLC, TX, USA).
Results
Eighty-three patients were eligible and included in the analysis. The median age was 67 years (interquartile range
[IQR], 58–76 years); 49% (n = 41) were males. At T-VEC initiation, most patients had AJCC 8th edition disease
stage IIIB (n = 19, 23%) or IIIC (n = 31, 37%); 28 patients (34%) had stage IV disease at the start of T-VEC
treatment. Median follow-up time was 12 months (range: 0–25 months). Patients received a median of seven
T-VEC treatments with median treatment duration of 3 months (range: 0–20 months) and a cumulative median
volume of 12 ml. Forty-six of the 74 patients who discontinued treatment (62%) received subsequent treatment.
Patient demographic and treatment characteristics are presented in Table 2.
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Table 3. Incidence of adverse events among treated patients by treatment regimen.
Overall cohort
(n = 83)

T-VEC after PD-1
(n = 22)

T-VEC concurrent
with PD-1 (n = 32)

T-VEC without PD-1
(n = 29)

Systemic AE†
– Fatigue
– Flu-like symptoms
– Muscle ache
– Vomiting
– Other‡

9 (11%)
4 (5%)
7 (8%)
1 (1%)
3 (4%)
3 (4%)

2 (9%)
–
2 (9%)
–
1 (5%)
2 (9%)

3 (9%)
1 (3%)
2 (6%)
–
–
1 (3%)

4 (14%)
3 (10%)
3 (10%)
1 (3%)
2 (7%)
–

Injection site AE†
– Rash
– Injection-site pain
– Ulceration
– Erythema
– Inflammation
– Other§

13 (16%)
2 (2%)
3 (4%)
1 (1%)
1 (1%)
1 (1%)
6 (7%)

1 (5%)
–
–
–
–
–
1 (5%)

4 (13%)
–
1 (3%)
1 (3%)
1 (3%)
1 (3%)
1 (3%)

8 (28%)
2 (7%)
2 (7%)
–
–
–
4 (14%)

† Patients

may have more than one adverse event.
were weakness, nausea and hypopituitarism.
§ Others were bleeding, pruritis, pressure sensation headache on top of scalp, shingles rash due to varicella zoster virus infection.
AE: Adverse event; T-VEC: Talimogene laherparepvec.
‡ Others

Patients were grouped into three categories: T-VEC initiated during or after anti-PD-1, T-VEC concurrent
with anti-PD-1 and T-VEC without anti-PD-1. Patients in the first category started T-VEC at a median time of
3 months after the last anti-PD-1 therapy, with therapy starting as early as simultaneously with last anti-PD-1 (0
months) or as long as 19 months after last anti-PD-1.
Aside from anti-PD-1 therapy, 33% of patients received anti-CTLA4 and 7% received BRAF/MEK inhibition
prior to initiation of T-VEC (Table 2). When T-VEC use was analyzed relative to treatment with anti-PD-1
inhibitor therapy, 22 patients (26.5%) received T-VEC after anti-PD-1 inhibitor therapy, 32 patients (38.6%)
received T-VEC concurrently with anti-PD-1 therapy and 29 patients (34.9%) did not receive anti-PD-1 inhibitor
therapy before or during T-VEC treatment. Among the 29 patients that did not receive anti-PD-1 inhibitor
therapy, the median age was 71 years (range 64–77 years). Most (83%) had stage IIIB–IVM1a disease and 66%
were BRAF-wild-type. Anti-PD-1 drugs, including pembrolizumab or nivolumab, were the most commonly used
agents regardless of sequencing with T-VEC.
Study outcomes from the chart review were as follows: nine patients (10.8%) were still receiving T-VEC injections
and 74 patients (89.2%) had discontinued at the end of the study. Twenty-one patients (25.3%) completed treatment
with no remaining injectable lesions (local complete response.). Median time to no remaining injectable lesions was
4 months (range: 1–20 months). Twenty-six other patients (32.3%) had died; 19 died due to disease progression
(73%) and the cause of death was not reported for seven patients (27%).
Reported select adverse events (AE) during treatment were divided into two categories: systemic and injection
site AE as no herpetic events were reported (Table 3). The most common systemic AE was fever, chills, and
rigors (seven patients, 8%). Other systemic AEs included fatigue, muscle aches and nausea/vomiting. The most
commonly reported injection site AE was pain (three patients, 4%); other reported AEs included rash, ulceration,
erythema and inflammation. Although variability across treatment groups was observed, no conclusions can be
drawn due to the study design and small sample sizes.
A survey was provided to one physician at each institution to understand physician treatment decision-making
related to T-VEC usage. Responses were received from all seven institutions (Table 4). Most physicians initiated
T-VEC therapy for curative intent or to decrease the size of lesions to allow for resection. All of the surveyed
physicians indicated that T-VEC should be administered in combination with systemic checkpoint inhibitors and
all would consider discontinuing T-VEC injection when there are no injectable lesions or if patients experience
AEs.
Discussion
Our study demonstrates that at high-volume academic and specialty centers in the real-world setting, over two-thirds
of patients treated with T-VEC received it with immunotherapy – either concurrently or following immunotherapy.
The select AE profile was similar in those patients that received T-VEC as a single agent or in combination with an
immunotherapy. The majority of T-VEC use was in patients with local or regional disease (63/83). Although 39%
(32/83) of patients in this study received T-VEC concurrently with PD-1 checkpoint inhibitors, physician surveys

Melanoma Manag. (2020) 7(2)

future science group

T-VEC use in the anti-PD1 era

Short Communication

Table 4. Physician perception of talimogene laherparepvec as a treatment option in the anti-PD-1 era.
Survey question and response statements†

n (%)

Number of institutions responding

7 (100)

What considerations led to T-VEC use in your patients?
– Treatment of local lesions with curative intent
– Priming for future systemic immunotherapy
– For improvement of current systemic immunotherapy
– Reducing size of lesions to make patient resectable
– Reducing the size of the lesions for symptom control
– Other treatment strategy

4 (57)
2 (29)
5 (71)
4 (57)
2 (29)
0

When should systemic checkpoint inhibitors be used with T-VEC treatment?
– Before T-VEC treatment
– In combination with T-VEC
– After T-VEC treatment
– Timing of checkpoint inhibitor administration is irrelevant to T-VEC treatment
– I do not believe checkpoint inhibitors should be used in a treatment regimen with T-VEC
– I do not have enough experience prescribing these treatments to provide a response

2 (29)
7 (100)
3 (43)
0
0
0

When would you consider stopping T-VEC treatment in a patient?
– No injectable lesions
– Clinical complete response
– Pathological complete response
– First incidence of increasing lesions
– Increasing size of existing lesions
– Local progression
– Regional metastases
– Distant metastases
–Adverse events
– I have not yet discontinued T-VEC therapy in a patient

7 (100)
6 (86)
6 (86)
1 (14)
4 (57)
1 (14)
2 (29)
2 (29)
7 (100)
0

† Responders

asked to evaluate each question and selected all responses reflected their use of T-VEC therapy.
T-VEC: Talimogene laherparepvec.

from these centers indicate that most clinicians feel that T-VEC is effective in combination with anti-PD-1 and
anti-CTLA-4 antibodies and that there may be synergistic effect due to immune priming. The present COSMUS2 study is a follow-up study to COSMUS-1 and characterizes the evolving landscape of melanoma treatment.
COSMUS-1 reported 43% of T-VEC treated patients received any checkpoint inhibitor prior to or concurrently
with T-VEC, and within 2 years, we observe an increase to 65% with anti-PD-1 treatment options specifically for
melanoma patients [4].
Despite the observational nature of this study, we observed no remaining injectable tumors (local CR) in 25%
across all treatment groups. In similar real-world chart review studies of T-VEC use, no remaining injectable were
noted in 11–20% of patients [4,16]. Additionally, an ongoing study by Sun et al. of T-VEC as second- or later-line
therapy after failure of immunotherapy reported no remaining injectable lesions in 25.5% of treated patients [sun
j et al. (2020) submitted], which is consistent with the data seen in COSMUS-2 and other similar real-world
studies.
There are few published clinical studies investigating the combination of systemic immunotherapy and T-VEC.
A case series of by Chesney et al. reported on two patients who had failed multiple lines of systemic therapy [17].
They reported a durable CR in one patient and a PR in the other and upon analysis of the tumor microenvironment,
confirmed evidence of lymphocytic infiltration, leading the authors to conclude that T-VEC may induce tumor
immunogenicity and be an effective treatment option in combination with systemic immunotherapy. Furthermore,
a randomized Phase II study demonstrated superior objective response rate with T-VEC plus ipilimumab versus
ipilimumab alone [18] and a Phase IB study of T-VEC plus pembrolizumab demonstrated a 43% CR rate by
immune-related response criteria and a 71% OS rate at 3 years with evidence of T-cell infiltration and favorable
tumor microenvironment with this combination [8,19].
Compared with our previous chart review study, the observed select AE profile in this study is consistent with
that published in our previous chart review study, COSMUS-1 [1,3,4,20]. The most frequently reported systemic
AE was flu-like symptoms and the most frequently reported injection-site AE was pain. The incidence of select
AEs did not increase among patients treated after or concurrently with PD-1 therapy and immune-related AEs
were not reported for any patients despite higher proportion of patients receiving T-VEC in combination with
anti-PD-1 inhibitor in this study. However, among the eight patients that discontinued T-VEC due to AEs, a
higher proportion were in the PD-1-treated treatment groups. AEs as reasons for discontinuation included grade
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2 colitis (n = 1), weakness (n = 2), discomfort/pain (n = 2), chest pain (n = 1), flu-like symptoms (n = 1) and
worsening functional status (n = 1). Autoimmune AEs, such as diabetes, hypothyroidism or myocarditis were not
reported for any patients. Clinical studies of the combination of T-VEC and immune checkpoint inhibitor therapy
have reported AEs profiles consistent with those seen with both agents individually [8,18,21]. Incidence of select AEs
do not seem to differ between patients treated with combination therapy or T-VEC monotherapy. None of the
studies, including this study, reported development of herpetic simplex lesions in patients treated with systemic
immunotherapy prior to or concurrently with T-VEC.
The combination of T-VEC and systemic immunotherapy for the treatment of unresectable metastatic melanoma
has been reported in published studies demonstrating efficacy of this treatment strategy. Our study provides support
that physicians at high-volume treatment centers have recognized this as a potential treatment strategy and now
use T-VEC to augment systemic immunotherapy in some of their patient cases. This study is limited by the
observational and retrospective design, including some incomplete medical records. Selection bias was minimized
by defining a time period wherein all patients treated with T-VEC were included. The findings of these studies
should be confirmed by future studies designed to evaluate treatment efficacy.
Conclusion
In the real-world clinical setting, T-VEC is used concurrently with or after anti-PD-1 inhibitor-based therapy about
two-thirds of the time. T-VEC remained tolerable when used with anti-PD-1 inhibitor therapy with few patients
discontinuing T-VEC due to adverse events. Randomized studies are underway to confirm the efficacy and safety
of T-VEC in combination with immunotherapy.
Summary points
• Talimogene laherparepvec (T-VEC) is an oncolytic virus approved for intralesional therapy of unresectable,
cutaneous, subcutaneous and nodal metastatic melanoma recurrent after the initial surgery.
• Review of patients treated at seven high-volume academic centers demonstrated use of T-VEC primarily after or
concurrently with systemic immunotherapy.
• 25% of patients completed treatment with no remaining injectable lesions (local complete response).
• In the select adverse events that were evaluated in this analysis, the T-VEC adverse event profile did not change
due to combination therapy, with the most common being flu-like symptoms and injection-site pain.
• Physicians surveyed at these institutions indicated that T-VEC is best used in combination with systemic
immunotherapy agents.
• T-VEC use among these high-volume melanoma centers is concurrent with or shortly after systemic
immunotherapy.
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